Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Patient and medicines safety)

Innovation 'Elevator Pitch':
Sensium Wireless Vitals Monitoring is proven to lead to treatment of sepsis 6 hours quicker than NEWS, reduce LOS by 10% and readmission by 45%. The only wearable vital sign monitor with peer reviewed RCT data showing significant clinical benefits. 
Overview of Innovation:
In general care areas of a hospital vital signs are typically taken during routine observation rounds once every 4-8 hours. If a patient deteriorates between these observation rounds the warning signs can go undetected for hours, potentially leading to serious & costly consequences. 
 
Sensium is a discreet, wearable, wireless system for monitoring vital signs of patients outside of high acuity areas. A light comfortable sensor worn on the patient’s chest accurately and reliably monitors and reports vital signs, providing data every 2 minutes. By notifying clinicians of changes in patients’ vital signs Sensium brings the nurse to the deteriorating patient, allowing intervention before the condition worsens, thereby improving patient outcomes, shortening hospital stays and lowering treatment costs. It enables nurses to prioritise patient care where it is needed most.   Sensium is focussed exclusively on general care clinicians whose patients currently do not have the safety and security of continuous vital sign monitoring.
 
The Sensium Patch provides accurate and continuous monitoring of the 3 key leading indicators of patient deterioration: heart rate (HR), respiration rate (RR) & axillary temperature (T). Sensium wirelessly communicates this physiological data via safe and secure low power wireless communication to the Sensium bridges placed through the ward area.  Sensium allows patients to ambulate freely, untethered to static and expensive equipment whilst still having the reassurance of continuous monitoring.
 
The bridges are connected into the hospital IT system, and software installed on the hospital network allows patient data to be seamlessly conveyed. Crucially, notifications can be configured to work with hospital pager systems/mobile notification devices, giving the clinical team data when they need it, where they need it. To save time and ensure accuracy Sensium can be easily integrated with the hospital admission, discharge, transfer systems and electronic medical records.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Currently approximately 10% of patients are harmed during their hospital stay and this represents a cost to the NHS of over £2.5bn just to cover the additional length of stay for these patients. Improved monitoring regimes and early detection of deterioration is key to reducing this significant burden.
 
Patients undergoing major abdominal surgery have an 30-40% risk of complications with a leading complication being sepsis. Hospital acquired (HA) sepsis (e.g. sepsis that develops after a surgical procedure) has twice the mortality rate and twice the treatment cost of community-acquired sepsis and rates of HA sepsis are rising. A recently-published study aimed to assess differences in outcomes between patients being monitored using the Sensium system in addition to intermittent (routine) observations and patients being monitored by routine observations alone [1].  The study was designed as a pilot cluster-randomised, prospective, parallel-group, controlled single-centre pilot study and consenting participants were allocated to one of two monitoring arms for the length of their admission. The primary outcome measure was time to antibiotics after the first evidence of sepsis, defined according to a revised consensus conference definition in 2001 [2]. Secondary outcome measures included length of hospital stay, 30-day readmission rate, mortality and patient acceptability. 226 patients were randomised between January and June 2017. 140 patients were randomised to continuous remote monitoring; 86 patients were randomised to receive intermittent monitoring alone. There were a similar number of complications and sepsis events across both arms of the study, indicating that both groups had similar baseline risk factors.

On average, patients receiving Sensium continuous monitoring were administered antibiotics 6.4 hours sooner after evidence of sepsis, had a 10% shorter average length of hospital stay and were 45% less likely to require readmission within 30 days of discharge than those patients in the intermittent monitoring group. Patients found the monitoring device to be acceptable in terms of comfort and perceived an enhanced sense of safety. Given that every hour’s delay in treatment of sepsis has been shown to be associated with a 7% increase in risk of mortality [3], a 6-hour reduction in time to administer antibiotics is a significant result and further studies are ongoing to demonstrate similar benefits in other clinical settings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Sensium’s solution offers several key benefits to the West Midlands and its population. The key benefits of Sensium compared to competitor products are as follows:

Product Performance: Sensium uses clinically accepted ‘gold standard’ methods of vital sign measurement, deriving heart rate from single-lead ECG, respiration rate from thoracic impedance, and temperature from an axilla sensor.  In contrast, our competitors derive respiratory rate from pulse or ECG measurements which has known limitations in certain clinical conditions and provide only skin temperature measurement which has limited clinical value.

Customer Focus: Sensium is recognised by our customers for exceptional customer support.  Once we deploy our product at a clinical site, we provide on-site technical support for installation and troubleshooting and clinical support for training for as long as it takes for the system to be truly embedded in the clinical workflow and providing tangible benefits. Sensium has clinical and technical staff based in the West Midlands region on hand for support.

Clinical Evidence: Sensium understand that medicine is an evidence-based science and we are engaged in a series of clinical research studies designed to show clinical efficacy, improved clinical outcomes, and health economic benefits.  To date, Sensium are the only company providing wearable wireless technology for early detection of patient deterioration that have independent and peer-reviewed publications showing benefits of our technology demonstrated through randomised controlled trials
 
 
Current and planned activity: 
Our initial engagement with the NHS has been to introduce Sensium to general surgery wards and areas with high risk and infection prone patients e.g. colorectal, trauma and haematology wards. Discussions with many NHS hospitals have also shown significant interest and benefit for the use of Sensium for ‘Step down’ areas for patients who aren’t sick enough for ITU but still show cause for concern and for high risk conditions such as Hospital Acquired Sepsis opioid depression and AF. 

We have engaged with the Emergency Laparotomy Collaborative with a view to patch these types of patients. When approaching the NHS, we have been primarily engaging with Anaesthetists as they witness many patient deteriorations, as well as consultants and sepsis/patient deterioration leads, matrons and clinical IT leads. We plan to interact more directly with medical directors and members of the directorate earlier on in the process if possible. Future plans include home monitoring to follow patients’ home.
What is the intellectual property status of your innovation?:
CE mark and FDA 510(k) cleared.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
2
Co-Authors:
Read more
Hide details
Sonia Hussein 18/05/2019 - 11:34 Publish 4 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Detection of acute, chronic and very early stage diseases in real time based on tests results and alerting all authorized parties about detected problems with of the essential patient information on mobiles, tablets and computers.
Overview of Innovation:
As it could be integrated and is constantly receiving data from current lab and EHR systems, it immediately detects problems in lab test results and informs doctors about new lab data received and issues detected for a particular patient. It gives access to historical data with some valuable statistical calculated and visualised data which helps doctors to understand acute, chronic, hidden or early stage health problems over secure web/mobile/tablet applications, so doctors can see these results for making better and correct decisions any time and in any location they are in at any moment.
 
Core applications of the solution are:
1. Speeding up doctors’ workflow in hospitals. At the moment, doctors in NHS have to go to rooms where there are computers with access to lab data. Quite often, doctors spend time waiting for each other to get access to their patient blood test data.

An essential part of the solution is the mobile/tablet application which can be installed on any mobile operation system iOS/Android. Which lead to:
  • Freeing up to 2 hours of doctors’ time daily
  • Increasing patient turnaround time on average by 25%
  • Increasing time reaction on most critical acute cases up to 99% 
2. In Doctors’ practice, there have been cases when a delay in days, hours or minutes in getting lab data in time is crucial for a patient’s life.  

Platform is constantly tracking blood data from the lab system, it analyzes it and alerts about critical changes in lab tests metrics and it immediately sends notifications to related parties to pay attention on a particular case.

At the moment, it tracks more than 25+ diseases and all other blood test parameters and (early and acute): AKI + CKD (all types), Sepsis and much more.

3. Platform provides historical analysis tools for blood results and gives some related insight information for each particular test parameter, so it is quick and easy to see the problem and identify potential problems at a very early stage and apply preventive actions to avoid problems. 

4. Platform has a recommendation system which seeks potential hidden problems in results. If those potential hidden problems are found, the platform gives an explanation and list of additional tests required to confirm potential problems.

5. For management team it provides deep business insight (visulised with over the time progression) of a difference scale: Hospital, Groups of Hospitals and National level about detected problems, about performance of laboratories, doctors and etc.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential impact of the Pin.Health on NHS
 
Product results in efficient improvements:
—  Increases time reaction on most critical acute cases up to 99%, that decreases the amount of fatal cases in hospitals
—  It frees up to 25% of doctors and GP’s time daily
—  Increases patient turnaround on average by 25%
—  Saves money on unnecessary blood tests and use of hospital beds

Product results in cost improvements:
—  It saves more than £18,000.00 GBP per doctor per annum
—  Decreases amount of unnecessary admissions up to 25%
—  Increases revenue up to 20% with the same medical headcount for commercial healthcare companies
—  Decreases the amount of unnecessary sales and blood test results in labs
—  Significant healthcare budget decrease on investment in huge IT project
 
Product results in patient care improvements:
—  Increases time reaction on most critical acute cases up to 99% that decreases the amount of fatal cases in hospitals
—  Early stage disease identification with more than 95%+ accuracy rate, and it keeps growing. It prevents serious illness conditions — move focus to preventative medicine
—  Decreases amount of fatal cases at the Hospital
—  Decreases number of doctors’ errors or human factors
 
Pin.Health supports the HSCIC Strategy (NHS Digital) 2015–2020 Strategy as well as some general European Union Strategies in Healthcare.
  1. Ensuring that every citizen’s data is protected
    Platform follows HIPAA, GDPR and UK Law in relation to data access and protection. 
  2. Establishing shared architecture and standards so everyone benefits
    Platform has API based on industry-standard protocol FHIR HL7 (JSON based protocol). Any trusted (pre-authorized by NHS) 3rd party applications and systems can connect to Pin.Health over a secure connection over API and get access to data it has, and results it has produced. 
  3. Implementing services that meet national and local needs
    As platform provides access to data and results it produced over API — any external trusted applications/systems can be built on top of it to solve other problems.
  4. Making better use of health and care information
    Pin.Health solves numerous problems which helps improve workflow in hospitals, speed up process of disease identification to save patients’ lifes and to avoid critical conditions, moving the focus to preventive medicine, proceed researches based on data platform aggregates. All of it implements better use of health and care information.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
In some doctors’ practices, there have been cases when a delay in days, hours, or even minutes in getting lab data in time is crucial to a patient’s life. Our platform solves this such challenges.

The platform is monitoring data from 3 perspectives — first it’s trying to detect acute diseases, after it recognizes chronic conditions and early stage conditions for each newly received test.
 
At the moment, we are tracking more than 25 diseases such as Acute Kidney Injury and Chronic Kidney diseases of all types, Anaemia of all types, Liver Disease and others, as well as all test parameters, whether they are out of range or not, and if they are at a chronic stage or an early stage.
 
One example is the AKI (Acute Kidney Injury) which is one of the diseases that is tracking in our system. AKI is a sudden and recent reduction in a person’s kidney function.  Despite the high incidence, AKI in hospitalized patients is characterized by a high rate of missed diagnosis. The missed diagnosis rate is about 57% even in high-income countries. In the UK, 1 in 5 emergency admissions into the hospital are associated with AKI, with up to 100,000 deaths each year in hospitals associated with acute kidney injury. From official UK NHS statistics, up to 30% could be prevented with the right care.

All in all platform leads to NHS operational, financial improvements as well as in longer and stronger health of the West Midlands population.
Current and planned activity: 
We would be interested in running the pilot project with one of the NHS Trust or Hospital for a period of 2-4 months. Afterwards, integration will be completed. To gather statistic about platform performance and getting first feedback from clinical environment, which leads to futher platform improvements and scaling benefits which platform gives over other NHS Trusts.
What is the intellectual property status of your innovation?:
Company is IP holder of the solution.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 05/12/2018 - 00:09 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Clinical decision making improved via proactive digital remote monitoring. Together driving cost efficiencies, improving patient outcomes & avoiding hospital admissions. (CE Class 1a: data server sits within HSNC:  proven ¯ 67% admissions: scalable)
Overview of Innovation:
CliniTouch Vie is a digital health solution that reduces unnecessary hospital admissions.
 
CliniTouch Vie is a locked-down tablet with integrated 3G for intensive monitoring, education & empowerment with integrated direct messaging & video support.  Dynamic care plans & evidence-based algorithms enable automatic triage for healthcare teams.  Fast & simple to implement for the most at-risk patients. 
 
Launched in 2016, system is CE marked & MHRA approved. An evidence based digital health platform that clinically supports patients to better manage their condition. It has the flexibility to be adapted for data analytics & clinical decision-making support in chronic disease management (eg COPD, heart failure & diabetes), frailty & assisted discharge programmes for ambulant & non-ambulant patients
 
Clinical & economic evidence has been generated from trials with 300 respiratory patients [Ghosh et al, 2016, https://doi.org/10.12968/bjhc.2016.22.3.123]. Our evidence based digital solution increases patient access to care & promotes greater clinician-patient collaboration for the 15million people with LTCs. It drives timely, proactive intervention, minimising need for more acute costly care enabling sustainable long-term outcomes success
 
USPs:
Evidence based: Study published in the British Journal of HC Management showed 67% reduction in unscheduled COPD admissions & saving of £2,278 per patient pa. (NB: programme continues to deliver same level of savings)
 
Patient-centred: Personalisation of goals, metrics & parameters makes system truly patient centred providing real-time remote monitoring closer to home to improve patient experience & outcomes whilst generating savings
 
Secure & integrated: Data server sits within HSNC enabling it to push-pull data securely between healthcare provider & service users. Includes bespoke integrated secure video-conferencing platform with end-to-end encryption, allowing remote monitoring of medical conditions, improving quality of life & avoiding unnecessary admissions
 
Flexible Modular Architecture: Enables clinically validated question sets re: symptoms, to be easily tailored to specific therapy areas for qualitative data collection
 
Tiered Service: no upfront costs to NHS on PAYG basis:
- Digital platform integrated into existing healthcare pathways
- Light touch triage service informing local health teams of urgent priority patients for interventions
- Fully-Managed digital platform and nurse-led service providing triage & interventions
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
CliniTouch Vie has proven benefits and can be scaled up easily across the wider regions:
  • improved patient outcomes:
  • 67% reduction in COPD emergency admissions;
  • 13% improvement in CAT score
  • 97% of patients using CliniTouch Vie will further reduce distress and discomfort from conditions exacerbations
These were supported by:
  • improved access to healthcare: 24/7 access to healthcare, average 110 interventions per patient per annum (500% increase)
  • targeted and personalised health interventions: 7,250 personalised clinical interventions (data from 66 patients over 12 months)
  • data analytics: real-time clinical dashboards for clinical teams to prioritise patient needs; prioritised only 38% of patient clinical recordings required intervention within a 24-hour period
 

 
Patients are educated and supported to interpret the data to gain an improved understanding of their health status.CliniTouch Vie:
  1. Educates patients: supporting people to make health life choices through improving the understanding of their disease and self-management skills
  2. Enhances care for patients with chronic conditions: informing and engaging patients as part of NHS prevention agenda and creating a patient-provider collaboration
  3. Provides data analytics: making more targeted and personalised health interventions, by using disease specific algorithms to differentiate when one patient’s history or recent environmental exposures indicates a higher likelihood of flare up than another
  4. Improves patient safety: providing real time clinical and well-being data to identify early warning signs of health deterioration, medication adherence and self-management education
  5. Reduces hospital activity: providing real time management of high risk patients to prevent admissions
  6. Supports early discharge: providing hospital level diagnostics and monitoring in the home, enabling early discharge and can be used for remote clinical support post-surgery or in care-home settings
  7. Delivers workload efficiencies: supporting better patient self-management, reducing need for direct interventions and enabling staff to focus on priority patient care
  8. Offers locality wide cost savings: reduced demand leads to reduced NHS activity
 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands priorities that CliniTouch Vie can address are:
  • P2: Long Term Conditions: whole system, person centred approach
  • P4: Wellness, healthy aging and prevention of illness
  • P8: Digital Health
 
Our vision is for CliniTouch Vie to contribute towards and support the West Midlands wider vision to develop a worldwide reputation for delivering healthcare through digital technologies, proven to deliver sustainable improved outcomes and create wealth.  We have already demonstrated that it can deliver on all fronts with high risk COPD patients and is being adopted for Heart Failure, Diabetes, Cancer and Frailty pathways.  With an ageing population, often with co-morbidities, it can be used to support a more patient-centric approach to health care services in the region.
 
CliniTouch Vie supports health and wealth benefits as is a flexible, real-time remote monitoring solution, facilitating earlier discharge, prevent readmissions, reduce risk of future exacerbations and improve self-management through our inbuilt education resources.  CliniTouch Vie delivers a proactive approach to tackling symptoms, preventing exacerbations and slowing health deterioration, resulting in reduced NHS costs.  The system has an extensive data collection of medical, lifestyle, biometric and daily activity.
 
Targeting patients who are at risk or have multiple hospital admissions could significantly reduce the NHS costs to the region as well as freeing up clinic and nurse time to manage a wider caseload more efficiently. With a more collaborative, integrated, patient centred approach, utilising proven remote digital health, the West Midlands could see a potential reduction in admissions by 60%+.
 
CliniTouch Vie is a locked-down tablet, with integrated 3G for intensive monitoring, education and empowerment with integrated direct messaging and video support.  Our dynamic care plans and evidence-based algorithms enable automatic triage for healthcare teams. 
 
The tablet comes in an easy to carry case with the peripherals and can be handed to the patient at home, in clinic or upon discharge and is linked directly to the clinician web-based management portal.  Data within CliniTouch Vie tablet is stored securely within the cloud and hosted on the N3.  This makes CliniTouch Vie easy to scale due to its low technology and estates requirement, whilst delivering a high quality clinical service.
Current and planned activity: 
Current:
Spirit Digital is part of Spirit Health Group and can provide one of the most comprehensive range of solutions to support patients of all ages, IT capabilities & levels of disease severity across a wide range of conditions e.g. respiratory, cardiovascular, diabetes, cancer, frailty.
 
Spirit is establishing research collaborations with academic institutions around evidence generation for AI and machine learning. This includes collaboration on a bid to the European Space Agency to further develop the technology using satellite data.

Planned:
Spirit Digital seeks WMAHSN support ta assist with introductions and marketing of CliniTouch Vie to local CCGs. 
 
Our planned NHS engagement activity programme for the next 12 months will be through a variety of channels:
  • Direct engagement with CCGs and community Trusts
  • Application to Digital Accelerator programme
  • Case study development & sharing
  • Presentations at national conferences
  • Creating user (clinicians & patients) video footage to share with CCGs
What is the intellectual property status of your innovation?:
We hold the IP for the technology and digital health algorithms.  We collaborate with Midlands based businesses, healthcare providers and universities and retain all IP for products and services.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Emma-Jane Roberts 21/06/2018 - 12:25 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
QxMD is a company dedicated to creating point-of-care applications created by for healthcare professionals, with a global community of 1.9 million clinicians, medical students, scientists and researchers and are free to download and use at any time. 
Overview of Innovation:
Healthcare professionals need to stay up to date on the latest medical research and topic reviews to provide optimal care. Unfortunately, the process of content discovery is broken with research artificially compartmentalised by publishers and hidden behind countless institutional paywalls.

At QxMD, we believe that knowledge translation– the process by which new knowledge is incorporated into clinical practice – is an important and unsolved challenge for our health care system. Read uses smart algorithms to ensure that each and every user has a dedicated newsfeed of research that applies to their practice. 
With Read, Institutional Edition, organisations can seamlessly integrate their existing journal subscriptions and existing proxy service to provide a platform for their clinical staff to access content which matters to their individual practices. It is built with features designed to improve patient care and reduce costs. 

The Promoted Research feature is used by institutions who want to disseminate research that impacts areas of care the most within their organisation. For example, a Hospital with high rates of Sepsis can use this tool to promote guidelines that reduce Sepsis cases with higher guarantees their clinical staff will discover the research and apply it to the next patient. 

Librarians and Knowledge Managers can take advantage of smart analytics to understand which journal subscriptions are performing the best and worst and also which journals are most popular, which they don't subscribe to.

NHS Trusts are already adopting QxMD, with over 100,000 users in the UK alone. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Better educatad and up-to-date staff, specific to their practice
  • Cost saving on journal subscription costs
  • Improved patient care
  • Challenges identified and tackled via the Promoted Research feature
  • Easy to discover and access research from any smart device
  • Links with OpenAthens for instant access to subscribed content. 
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
  • Better educated healthcare professionals who can identify the latest research and apply it to patient care
  • Less chances of mis/under diagnosis, readmission or even death
  • Improved quality of care
Current and planned activity: 
  • Existing NHS Trust clients, including the largest Mental Health Trust in the UK
  • Continue to grow our userbase, which is already at 100,000 UK users, with the support of Trusts and other stakeholders. 
What is the intellectual property status of your innovation?:
  • We have designed and developed the platform entirely in-house. No white-labelling. A completely unique tool built by Healthcare Professionals for Healthcare Professionals. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Jimmy Connoley 19/06/2018 - 12:56 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
‘Uber’ for the NHS. Hospitals crate shifts & push them to only the relevant candidates. Those interested apply with a single click. Hospital admins award the shift to the best candidate. When the job is done both sides leave feedback.
Overview of Innovation:
Megalist is a staff management platform.
The single biggest threat to the NHS is the staffing crisis which affects every other aspect of the NHS.
The is no reason why a large organisations like an NHS Trust with thousands of employees can not share employees to load balance their staffing needs. For example ITU nurses covering A&E.
The only reason for not doing that is that the NHS does not have the infrastructure to do such a thing - to load balance staff between departments, sites, hospitals or even Trusts.
It’s time to rethink the old model.
An NHS employee is an NHS employee and there is no reason that if the have the necessary skills that they wouldn’t be able to cover shifts in a different position in the NHS.
The agencies have been providing the NHS with this integrated infrastructure and charging a very hefty price for it and in all fairness delivering a mediocre service at best.
Megalist provides an innovative solution of a distributed staff management system.
Instead of one secretary calling and emailing everyone and then emailing or calling the agency who emails and calls the staff on their books and they email and call back to the agency who emails and calls the secretary who finds the consultant or the nurse in charge and they vet the agency worker and then they call and email the agency who calls and emails the doctor or nurse who might have taken another job already.
Megalist is a distributed staff management platform - meaning that many people have admin rights: senior doctors, senior nurses, site managers, secretaries, rota coordinators, departmental manages, night mangers and so on. They can all create a shift and push it directly to the relevant people who get the offer directly on their phone and who can respond with a single click.
Hundreds or even thousands of people can be notified in seconds and relevant candidates can be found in minutes not hours or days.
The admin awarding the shift has a lot more information at hand - feedback from previous shifts, how many shifts the candidate worked in the past and where, full electronic resume, photo, relevant documents in our document exchange and much more.
The main benefits are admin staff spend significantly less time finding staff and can do other tasks. Agency spending is cut drastically and having a fully staffed department means increased patient safety, increased patient satisfaction, increased employee satisfaction and thus higher productivity.
 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
The main benefits are admin staff spend significantly less time finding staff and can do other tasks. Agency spending is cut drastically and having a fully staffed department means increased patient safety, increased patient satisfaction, increased employee satisfaction and thus higher productivity.  
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Same as above but for the local polulation. 
Current and planned activity: 
We have ran a successful pilot in St. Thomas' A&E - for doctors only - SHOs and Registrars and in the 34 months which we were developing the platform we covered from them 1142 shifts. 

If you extrapolate that: 

Agency average margin £10 / hour / shift
Average shift 10 hours 

£3,4k / month / deparment / role (eg. doctors)
£40k / year / deparment / role (eg. doctors)

If an average department has 3 roles - doctors, nurses and nursing assistants, but most have more
And an average hospital has 10 departments but most have more 

Than the savings easily exceed £1M annualy.


Please see a short 60 second animation that explains the concept in more detail:

https://vimeo.com/232833427

And some testimonials from real end users.

https://vimeo.com/238748695/f23f1c6ce3
https://vimeo.com/239816983/781e206e76
https://vimeo.com/239817899/ed97fc21fe
https://vimeo.com/239818102/dfdad9f6ff

We are looking for help to get into and NHS Trust. 
What is the intellectual property status of your innovation?:
It is fully owned by Megalist Limited
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Appart from building our system we have build an adjacent system that stress tests our main platform and we have tested it to 5,000,000 users without any problems. 

We are ready to scale regionally and nationally. 
Measures:
We have proven that we can cover 40-65% of shifts that are posted trough Megalist. We would like to scale this and provide safer staffing levels across other NHS Trusts. 
Adoption target:
Ideally we would like to get the first paying NHS Trust on board - provide value for them and than with that scale regionally and nationally across the entire NHS. 
Read more
Hide details
Anonymous 09/11/2017 - 21:50 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Currently, a GP refers Obstructive Sleep Apnoea patients to an NHS Specialised Sleep Centre. Averaging 24 wks & 3-5 hospital visits before the Patient starts treatment.
Now, a GP with SOMNOtouch can receive results in 48-72Hours (3days vs. 6Mths)
Overview of Innovation:
Currently
The vast majority of patients with Obstructive Sleep Apnoea (OSA) are referred by their GP to a Specialised Sleep Centre at an NHS Hospital with a Average waiting time 12 Weeks


Patients are initially seen by a Consultant or a Sleep Physiologist who would prescribe a Diagnostic Study to be performed either in hospital or at the patient’s home. Average waiting time 12 Weeks
The patient returns to have the sleep study done or to collect the monitor and then returns the device the next day. After a further waiting time of upto 6 Weeks the patient visits the hospital again to obtain the results of the sleep study and if Positive, to discuss treatment.
A letter is sent to the GP informing them of the results and if agreed, a prescription is issued by the GP for the recommended therapy this may also take an average of 6 Weeks to arrive.
 This is prior to any treatment being administered such as a CPAP where if used they attend annually to check on compliance and progress.
 
This 6 month process is dramatically reduced by the S-Med Service to just a few days before an intervention can be delivered.


Now
The GP fits SOMNOtouch, a Combined OSA/Hypertension Monitoring Device to the patient, after 24 hours they return to the GP practice where the device is removed and the GP uploads the data from the device to a secure NHS Digital Cloud Server.
SOMNOtouch NIBP - Five devices in One
Video link: http://www.s-med.co.uk/Products#nav-product-86
 
S-Med Ltd’s Qualified and Registered Physiologists interprets the study and provides a recommendation for further treatment or investigation within 24 to 48 hours to the GP surgery. (All analysis and interpretations are supervised by a senior Consultant).
 
The report is sent to the GP who would then provide a prescription for the relevant therapy to be provided.
 
Thus within 48 to 72 hours a patient can be treated or directed for additional investigations or treatment before their condition deteriorates.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Faster response times and time to providing treatment from an average time from referral to treatment of 6 months (24 weeks) down to 4 to 5 days (1 week). With the added benefit if there are more critical underlying conditions then these may be picked up and dealt with quickly
 
Reduction in costs of patients being referred to NHS sleep centres thus less calls and pressure on such specialist clinics e.g.:
 
Reimbursement Tariffs for OSA and Hypertension
Current reimbursement guidelines from the Department of Health are:
  • For Ambulatory Sleep Diagnostic Study: £391.00
  • For 24-Hour NIBP Study: £268.00 (UCL NHS Foundation Trust, there is no NHS tariff)
  • For 24-Hour ECG Study: Recording - £268.00 plus Analysis £215.00 (UCL NHS Foundation Trust, there is no NHS tariff)
 
Cost Savings Calculation
Assuming the following:
  1. Adult Population of the England is Approx. 45 million
  2. BLF figure show approx. 10% of population suffers from OSA = 4.5 million
  3. DH figures show that approx. 30% of adult population has Hypertension = 13.5 million
  4. Public Health England shows that 1.3 million people have Atrial Fibrillation
 
The cost of referring 1% of the above population to hospital annually, will cost approximately:
  1. OSA – 45,000 £32 million per year.
  2. Hypertension – 135,000 £79 million per year
  3. AF – 13,000 £10.5 million per year
 
Total cost of £121.5 million
Cost of S-Med Service - £38.6 million
Savings to NHS = £83 million per year.
 
Aside from OSA, this equipment can be used for chronic heart conditions studies as well as more longitudinal studies adding a wealth of data for clinicians to inform them of patient’s conditions at work, rest and play without the equipment being intrusive and disturbing as current cuff based systems thereby removing the abnormal results they can provide. Thus, this equipment may also be of benefit to clinical trial units or during treatment to monitor the physiological effects experienced by patients undergoing a drug or other clinical interventions. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In addition to patients getting a faster diagnosis, it will reduce the burdens on NHS Trusts not only from the reduction on 1st line referrals to hospitals, but from patients conditions deteriorating, or suffering economic or social problems waiting 6 months for a diagnosis and treatment to be considered.

North West Innovation Agency (AHSN) will be conducting a pilot which will monitor 75 patients via a number of GP’s Practices. Results should be available by the End of February 2018.
As a West Midlands based company we would welcome an opportunity to work with NHS Trusts and CCG’s within the region to help us grow this service within the UK for the NHS and to increase our team to service and facilitate such requirements.  
Current and planned activity: 
Current NHS engagement
  • Embarking on a NIA application with North West Innovation Agency
  • Submitted an application into the ITP based on experience and adoption within the NWIA area.
  • Considering a NIHR project following a meeting at AHSN meeting - Speaking with West Midlands NIHR/CRN
Requested NHS engagement
  • Procurement / Adoption of: -  Would welcome assistance to gain greater Adoption by Trusts and CCGs within the West Midlands
     
  • Evaluation / Validation / Clinical Trial – Interested in trials for use of our ambulatory equipment (SOMNOtouch) within new clinical areas to show its versatility and extend its clinical use to provide validated evidence within in these new areas.
     
  • Project Assistance S-Med is interested in locating potential clinical / academic collaborators to engage in their current work and to explore other clinical applications of their technology.
What is the intellectual property status of your innovation?:
Device IP held by SOMNOmedics Germany. Clinical diagnostic and reporting service is owned by S-Med Ltd.
Reg. CE0494
We have obtained IGSoC Level 2 (ODS Code: 8JP12)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Read more
Hide details
Selwyn Sher 03/10/2017 - 13:27 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Complicated and laborious document production processes become easier to manage through intelligent workflow software that remembers and organises information with built-in reporting to manage production targets.
 
Overview of Innovation:
Epro Scrik is a third generation dictation, forms and documentation management mobile technology solution, designed by clinicians.
 
The solution uses a unique combination of structured data, dictation, templating, speech recognition and usability to revolutionise clinical correspondence and document production workflows for clinicians saving time and money. 
 
Scrik then leverages these a second time to enable clinicians to access and search patient documentation and notes quickly, presenting information in the fastest, most convenient way possible.
 
Complicated and laborious document production processes become easier to manage through intelligent workflow software that remembers and organises information with built-in reporting to manage production targets.
 
The solution is fully interoperable and very flexible. It can enhance legacy EPRs and integrate with legacy PAS systems. It can be combined with Epro’s wider group of clinical functionality for clinical workflow, patient journey and document management to help NHS trusts improve patient safety, increase efficiencies and achieve a paperlight working environment.
 
 
With Epro Scrik, you can:
 
  • Create templated clinic letters with just five clicks.
 
  • Make more informed medical decisions with greater access to current and historical information
 
  • Reduce risk of clinical errors by facilitating more legible, complete and accurate information
 
  • Meet your document delivery targets through faster letter production
 
  • Make better use of staff time and skills by removing or automating repetitive tasks
 
  • Save money on paper, printing and postage
 
  • Improve coordination and correspondence with other care providers, such as GPs
 
  • Increase clinical efficiency with speedy, consistent access to patient information at the point-of-care
 
 
 
Core features:
 
  • Capture clinical information with industry leading digital dictation, speech recognition and snippet technology
 
  • Enable mobile working for clinicians
 
  • Chronological view of historical patient information
 
  • View, manage and schedule clinic appointments
 
  • Integrate with / record SNOMED coded patient allergies information
 
  • Full visibility of patient admissions, transfers and discharges
 
  • Safeguard patient information by specialty or department
 
  • Electronically distribute documents to GPs and other care providers
 
  • Powerful reporting functionality
 
Links seamlessly with patient administration systems Import ad hoc documents 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
Video case study: Transforming clinical correspondence performance at Taunton and Somerset
Watch the video here: youtube.com/watch?v=uCJpF86jslo
Anticipated outcomes:
 
Epro worked with Taunton & Somerset NHS Foundation Trust to transform its clinical correspondence. The trust reported improved patient experience (due to speedier communication), decreased stress among staff, faster clinical access to patient letters, reduced clinical errors, and compliance with audit and access requirements.
  • £1.1m of secretaries’ and clinicians’ time
  • £11K on administrative costs £4.3K spend on printing
  • 96% reduction in letter transcription backlog
  • 100% compliance with 7 day letter delivery CQUIN

£4.3K spend on printing
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
We are launching a telemarketing campaign on the 6th June across the West Midlands offering a FREE of Charge Paperlight Clinic to any NHS Trust in the West Midlands.
Current and planned activity: 
We are launching a telemarketing campaign on the 6th June across the West Midlands offering a FREE of Charge Paperlight Clinic to any NHS Trust in the West Midlands.
What is the intellectual property status of your innovation?:
IP is with Epro only
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Keli Shipley 04/06/2017 - 22:43 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Monsenso is an innovation leader within mHealth for mental health, providing a Class 1 CE-marked medical application for data collection and sharing, to support better mental health at lower costs.
Overview of Innovation:
Monsenso is a solution that enables easy development and deployment of user-centred monitoring and feedback systems, which are tailored to a specific mental health problem, such as bipolar disorder. The system is configurable, which enables accommodation of clinical needs and easy implementation within clinical settings. The core of the system is to support a continuous monitoring and feedback loop that allow data to be sensed and entered by the individual, while the system then use this collected data to provide appropriate and situated feedback to the individual, as well as sharing data with a care provider and, if appropriate, a caregiver.


As illustrated in above figure, the Monsenso Solution provides individuals with a smartphone application, on which they perform daily self-assessments. Furthermore, the individual's’ physical condition can be monitored automatically through the embedded sensors in the smartphone. The system can detect behavioural changes through configured triggers and early warning signs to give individuals useful feedback.Furthermore, the app provides the individual with action plans for tackling certain situations that they might encounter.
All this information is visualised for the individual through graphs, and simultaneously synchronised in real time to a web portal for care providers, giving them the needed overview and information about their assigned individuals’ mental health. This way the care provider can channel efforts towards individuals who really need help and physical consultations. When the individual then comes in for a consultation, the care provider has a broad historical overview of the individual’s mental health over the past period, instead of relying on the individual to share this information.
 
The Monsenso Solution allows individuals to grant access to caregivers, to receive aggregated data regarding the individual through the app. This keeps caregivers informed remotely of the wellbeing of the individual, and enables them to provide input for both individuals and care providers. Not only does the solution keep the caregiver informed about the state of the individual, it also helps the caregiver cope in situations that might arise. 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Drew MacKenzie 29/03/2017 - 12:00 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
SMC provides an innovative, integrated, digital platform solution that deliver better patient outcomes, greater self-management and delivers healthcare more efficiently. The system is highly configurable and customisable and deployable at scale.
Overview of Innovation:
SPS have created an open, future proofed digital platform that harnesses and integrates a range of mobile, communication and wearable technologies to pre-emptively and pro-actively support improved patient outcomes while enabling more efficient healthcare service delivery across primary, secondary and social care environments.
Our mobile health (mHealth), telemedicine and telecoaching solutions use familiar mobile and ‘cloud’ based technology. It has been proven to  support service redesign and deliver more efficient, patient centric healthcare that’s cost effective, simple to use and easy to implement at scale.
Our ‘open’ architecture and web based platform enables more holistic Long Term Condition management services by leveraging a range of technologies across mobile, tablet, text, video and voice to deliver a highly flexible solution for healthcare professionals and patients. Mobile health (mHealth) enhances patient outcomes by enabling clinicians to pro-actively and pre-emptively monitor patients remotely while also enabling the individual to better understand and manage their condition that results in improved patient outcomes, reduced visits to hospital and local GP’s Surgeries.
Our SMCTM solution can be customised to meet any Long Term Condition (LTC), co-morbidity or medical condition that an individual may suffer from. It can support one or multiple LTCs, as well as any other health or mental health condition where a question or vital sign measurement can be of benefit. To date core commissioning has been focused on supporting people who suffer from Heart Failure, Coronary Heart Disease, Hypertension, Chronic Obstructive Pulmonary Disease, Asthma and Diabetes, but we have also developed profiles to support Urinary Tract Infection, Falls Prevention, Dementia and Depression management, Cystic Fibrosis, Obesity and end of Life.
The SMCTM solution is deployed across multiple CCG’s and provider in the UK with over 10,000 patients benefiting from the system over the past 5 years. We have supported different operational and clinical pathways, including effective system deployment into patient homes and Care Home environments that can then enable pro-active and pre-emptive alerts to be raised with a Clinical care team.  Our technology and services have also been selected by a wide range of organisations including BT Health, Alere, Welch Allyn, MSD Commercial, Healthcare @Home to support new and existing service models in the field of telehealth.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Key deliverables achieved with SMCTM solution:
  • Facilitate early patient discharge and reduce bed days: Harrow CCG, 2014: achieved a 50% reduction in unplanned admissions and 63% bed day reduction to deliver an ROI of 159% and net savings of £3,444 per COPD and cardiac patients.
  • Improve prevention and early intervention:  Derbyshire Community Hospital, 2014: achieved a 68% reduction in unplanned admissions; 415 bed day reduction across 187 patients in a 6 month period with a net saving of c£100,000.
  • Improve service value and efficiency of service provider: Bristol CCG, 2013: within just 30days of the telehealth service starting the number of contacts reduced by 26% with an 18% reduction in face to face time and 40% reduction in telephone contacts
  • Sustain independent living and improve patient outcomes: Birmingham Community Health, 2014: Surveyed 312 patients with 86% of patients stating system helped them manage their condition; 84% more involved in their care; 90% happy to reduce the number of routine hospital visits.
     
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
SMC offers multiple benefits for patients:
  • Personalised care modules: supports an individual's care needs using the most relevant questionnaires, vital signs and content.
  • Embedded educational content: on demand video aids training, behaviour change, understanding and the confidence for patients to self-manage their condition.
  • Sustains independent living: the use of relevant, integrated and familiar technology empowers patients to better understand and manage their conditions at home.
  • Easy to use and "out of the box": use fo familiar smartphones and tablets with wireless peripherals; audio and multi-lingual options.
  • Remote access and support software: touchscreeen enabled device support over the phone.
  • Video tele-consultation: remote "face to face" clinical consultation to aid better clinical intervention.
  • Text messaging: enable cost effective self-care.
  • Better patient outcomes: improves quality of life, reduces anxiety and increases confidence.
Current and planned activity: 
The SMC solution is deployed across multiple CCG’s and provider in the UK with over 10,000 patients benefiting from the system over the past 5 years. We have supported different operational and clinical pathways, including effective system deployment into patient homes and Care Home environments that can then enable pro-active and pre-emptive alerts to be raised with a Clinical care team.   Our technology and services have also been selected by a wide range of organisations including BT Health, Alere, Welch Allyn, MSD Commercial, Healthcare @Home to support new and existing service models in the field of telehealth.
We have long standing partnerships with Somerset CCG, Cornwall Foundation Trust Rotherham NHS Foundation Trust, and Dudley CCG and have been awarded innovator partnership on two Test Beds, one in Surrey and one in Manchester (with MSD Commercial.)

We support other conditions and pathways: Cystic Fibrosis, Falls and UTI, Spina Bifida children, LTC6 and E5QD quality of life.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Elisabeth Barbosa 12/01/2017 - 17:57 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
GroundVision provides the next generation of patient observations, and a range of dashboards, including our specialised Rapid Detection and Response (RADAR) view, to enable an efficient, proactive response to the deteriorating patient.
Overview of Innovation:
Over 6,000 people die every year in hospital as a result of “failing to rescue” a deteriorating patient. GroundVision provides a simple and cost effective system to record and calculate EWS (Early Warning Score) and a variety of other observations and assessments, from Bristol Stool to Fluid Balance, at the patient bedside to ensure that deteriorating patients are quickly and accurately identified.

As well as the ability to record patient observations at the bedside, GroundVision provides a variety of specialised views for different departments of a hospital:

Ward View
Displays information and observations about all patients on a ward.
 
Critical Care View
Displays information and observations about all patients in the Trust, with filtering capabilities, enabling searches for groups of patients (e.g. those that are deteriorating).
 
Infection Control View
Displays information about Bristol Stool Samples and infectious patients, enabling better control of infection outbreaks.
 
Ops Team View
Displays all side rooms in the hospital, with information about their occupancy, including a reason and priority for the isolation of a patient.
 
Dashboard View
Allows users to create customisable reports/graphs about a wide range of patient and observation related information.
 
RADAR (Rapid Detection And Response) View
Provides a view that shows all deterioration patients within their “score banding” who have not been responded to. The solution also graphically shows their health trajectory enabling healthcare staff to intervene before the patient triggers. This real-time view can be displayed via tablet, desktop or electronic whiteboard onsite or remotely.

Our solution has been developed alongside nurses, so it is easy to use as well as being low cost. It can be used on any device and accessed remotely as well as on site.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
GroundVision can provide a variety of benefits to the NHS:
  • Reduction in patient mortality
  • Reduction in hospital length-of-stay
  • Reduction in time taken to record/calculate Obs/EWS
  • Improvement in the accuracy of EWS calculations
  • Increased levels of clinical attendance
  • Increase compliance with hospital protocols
  • Reduction in the number of unexpected cardiac arrests
  • Fewer admissions to ICU
  • Reduction in the number of ICU days
  • Reduction in the number of infection outbreaks
As well as this, it brings the NHS one step closer to being paperless.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
It can help NHS organisations within the West Midlands area by improving patients safety and patient outcomes.
Current and planned activity: 
We have been engaged with Surrey and Sussex Healthcare NHS Trust, co-developing our solution alongside them and providing pilot projects, rolling out our solution to several wards.

We are also currently engaged with other NHS organisations within that area, such as Kent Community Healthcare NHS Foundation Trust.

We will continue to engage with as many NHS organisations as we can as well as continuing to develop our solution, to increase the wealth of observations and assessments that we have available to contribute towards improving patient safety.
What is the intellectual property status of your innovation?:
Simply Clever Ltd (trading as GroundVision) own the intellectual property 100%
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
2
Read more
Hide details
Anonymous 12/01/2017 - 17:24 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
More people die of SUDEP (Sudden Unexpected Death in Epilepsy) than in house fires every year.
 
Every home has smoke detector, so why shouldn’t all epileptics have a device that alerts people close by so that they can provide assistance when needed?
Overview of Innovation:
Embrace is the world’s 1st system for seizure detection based on analysing multiple physiological data sensed at the wrist.



Should someone with Epilepsy experience an ‘unusual event’, such as a convulsive seizure, an alert will be sent via their smartphone to parents, friends or caregivers, summoning immediate help. Additionally, a caregiver can also wear a 'companion' Embrace. When the two Embraces are within range (e.g. in nearby rooms), the 'companion' Embrace worn by the caregivers will vibrate to alert them.

The Embrace watch has received awards for its design & innovative technology. The watch monitors Electrodermal Activity (EDA), also known as Galvanic Skin Response (GSR), which is autonomic data that is activated by regions deep in the brain involved in emotions such as fear, anxiety & excitement.
 
Embrace watch also functions as a sleep monitoring & activity tracking device.
 
What else do Embrace sensors monitor?
Embrace comes with an app called Mate. Mate combines events that are entered manually with events that are sensed by Embrace. Mate helps see how patterns of sleep, autonomic stress, skin temperature and physical activity may interact with seizure events. (NB: initial release of Mate app features rest and activity information, while features like autonomic stress monitoring, are still in development and will be added later). For example, if there are an increased number of absence seizures when stress levels have been high and sleep has been irregular, then these can be tracked to see if changing these patterns reduces the number of seizures.
 
Embrace and Alert app system for seizure detection is for investigational use only. The system is currently not clinically proven to detect seizures. Evidence of seizure characterization using the technology in Embrace has been gathered in a number of clinical trials since the initial discovery of skin conductance changes during a seizure was published in 2012. Empatica is currently conducting clinical trials to evaluate seizure detection of generalised tonic clonic seizures (GTCS) using the Embrace watch & Empatica Alert app.
 
The automatic physiological data logging provided by the Embrace system is valuable when someone experiences a seizure as they may not remember what has happened themselves. A diagnosis is often based on finding out what happened to the individual before, during and after a seizure.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The number of people in the UK diagnosed with epilepsy has risen sharply in recent years. There are around 65 million people living with epilepsy in the world, with an estimated 600,000 people in the UK.
 
Every day in the UK, 87 people are diagnosed with epilepsy. Only 52% people with epilepsy in the UK are seizure-free.
 
During 2013, 1,187 people in the UK with epilepsy died earlier than expected (premature death). Some of these deaths could have been prevented. A clinical audit of epilepsy deaths in 2002 found that 64 per cent of adult deaths and over half of child deaths were possibly or probably avoidable.
 
Epilepsy is misdiagnosed in 20-30% of cases: most commonly, non-epileptic conditions are incorrectly diagnosed as epilepsy. Up to 40% of children referred to a tertiary clinic do not have epilepsy.  In 2004, the National Institute for Clinical Excellence (NICE) estimated the direct costs of epilepsy misdiagnosis (including inappropriate treatment, but not including individuals’ lost productivity from misdiagnosis) to be between £130m and £190m per year (NICE (2004) Epilepsy, second consultation, Appendix G).
 
Limiting the rate of misdiagnosis will help to reduce the risk of teratogenicity in wrongly diagnosed patients and will prevent patients wrongly diagnosed with epilepsy from facing, for example, unnecessary restrictions in employment and in other areas of life. Better diagnostic services are also likely to reduce any treatment gaps or inequalities, and, through encouraging independent living, improve the rate of employability for people with epilepsy. Finally, patients will have a greater choice of treatment options and a greater sense of empowerment
 
Epilepsy is an ambulatory-sensitive condition, meaning that better management in the community or primary care setting can effectively avoid unnecessary visits to the emergency department and non-elective hospital admissions.
 
Prevention of 15 admissions to hospital would Save the salary of a single epilepsy nurse
Estimate from National Audit of Seizure Management in Hospitals 2 (NASH2)
 
In 2009, there were 13 million prescription items of anti-epileptic drugs dispensed in the community in England, at a net ingredient cost of £300 million (NHS Information Centre Prescription Cost Analysis 2009. The net ingredient cost is the cost of the drug before discounts, not including any dispensing costs of fees).
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Epilepsy affects 54,000 people in the West Midlands (Source Birmingham City Council May 2016). The economic and social costs of managing this cohort is very significant.
 
Gaining control of one’s epilepsy not only saves direct health related costs in terms of fewer emergency or longer term hospital admissions, but also enables individuals with epilepsy to continue working and maintain their independence.
Current and planned activity: 
Current activity:
The Embrace device was only recently launched in the UK in November 2016. Currently clinical trials are taking place in the USA.
https://support.empatica.com/hc/en-us/sections/200817625-Seizure-Characterization-Clinical-Trial-monitoring-with-Embrace
 
We have taken orders from a number of Local Authority Assistive technology departments and are keen to engage further with the NHS.

Planned/future activity:
The published trial results cited above were from predicate devices. We need to collect more data using the Embrace and Alert app to complete the medical and FDA certification processes before we are able to make any claims regarding seizure detection performance of this system.
 
We are very keen to work more closely with any West Midlands network that provides support to people with Epilepsy or Autism.
 
What is the intellectual property status of your innovation?:
Patents Held by Empatica – further info available upon request.

The device is currently being fast tracked through FDA approval.

It also holds - Certifications:  CE Mark, FCC CFR 47 Part 15,  RoHS.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Ben Carter 19/12/2016 - 13:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A functional, digital, patient-centric, diabetes self-test system providing: self-care; patient-professional shared decisions; proactive interventions; complications prevention; data integration pan NHS provider; multi-faceted NHS costs savings.
Overview of Innovation:
awergq3wrg3w
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
wefefgvw
Benefit to WM population:
f23ef2e
Current and planned activity: 
23rwefw
What is the intellectual property status of your innovation?:
fwergq3r5g
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Baldev 31/10/2016 - 14:26 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
MyHomeReach is a digital platform that addresses Isolation, Medication Adherence, Chronic Disease Mngt and Maintenance of living environment. It provides personalized services key for the individual while delivering efficiencies to the care giver.
Overview of Innovation:
People want to age in the familiarity of their own homes. They want to continue with their daily routines while maintaining their independence in a safe and secure environment, in a way that contributes to their well-being and quality of life.
MyHomeReach™ enables independence with the reassurance that family, friends, and health care professionals are only one touch away, reducing stress and concern of isolation. This unique solution makes it easy, affordable, and convenient to connect a care recipient with their community i.e. care professionals, family members and social services.
Both formal and informal care givers are able to continuously interact, monitor wellness, record service, and react to alerts. Anyone that is important as a ‘care provider’ can be included in the community of care.
MyHomeReach™ enhances independent living with the comfort that assistance is only a touch away
Desktop/Tablet Application:
MyHomeReach™ makes it easy to manage calendars, share important information. The important resources, services, and community connections you need to age at home in a safe and secure environment are unified in this revolutionary approach to empowering independent living.
MyHomeReach™ simplifies connection to the network of care, medication & appointment reminders and the co-ordinating of schedules.
 
The Mobile Application:
MyHomeReach™ is also available on the go for Care Recipient and CARER via smartphone. In addition to the standard features the phone will have Personal Emergency Response (PERS) capability. Being lost, isolated or confused just press HELP. MyHomeReach™ will raise an alert and send details of your location making it easier and quicker for assistance to be received.
Connect with credentialed service providers so that seniors living independently have a trusted community-vetted resource for transportation, home improvement and service, plumbing, electricians, grocery delivery and other daily assistance
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Improved more efficeny delivery of service; 
•Reduced reliance on manual processes, with increased secure and robust automation of information collection, sharing and analysis to free up resources.
•Streamlining offices processes allowing more focus on client care
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Improved client experience;
•Clients will become active participants in their health care journey and be better informed on their treatment options which increases their engagement and understanding of their care
•Family and Friends engaged
•Ensuring better carer / client matches
•Ensure client concerns are heard and issues resolved via a quality tracking system
Current and planned activity: 
No current engagement with NHS
What is the intellectual property status of your innovation?:
There is no IP
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Paul Mooney 26/09/2016 - 16:59 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The Sound Doctor has over 250 high quality short educational films. Evaluations show they work by changing behaviours and improving outcomes to help people get the best out of life with long term conditions. 
Overview of Innovation:
The Sound Doctor is the leading provider of film and audio content for patients in the UK. Our content is thought to be unmatched in quality, range and production values and evaluations show it works by changing behaviours.and improving outcomes to help people get the best out of life with long term conditions.
 
Our films are endorsed by leading charities and adhere to NICE guidelines.
Conditions covered are COPD, Diabetes, back pain, dementia and weight management surgery.  A large series on heart conditions including cholesterol and hypertension, will be made shortly. 
There are over 250 films in our library so far and it is constantly growing.
We also create animations. We have a range of health and wellness short animations which are now being used in pharmacies and GP surgeries around the country. 
In addition, the team also devised and produce Health Today, a national radio programme for NHS England – nhs.uk/healthtodayradio
 
We have evidence that patients with diabetes, for example, have changed their attitudes towards diet and exercise as a result of watching our films. People with COPD are more confident about dealing with exacerbations at home. We also know that across all conditions they are considered a valuable part of people’s health care and improve patient experience.
 
The aims of The Sound Doctor, and there is evidence of this as well, are:
 
1. To reduce the number of avoidable admissions (and readmissions) to hospital
2. To reduce the need for face to face contact with consultants, physicians, nurses, physiotherapists and others (and to improve the quality of meetings which do take place)
3. To address the issue of co-morbidities by creating a multi-condition library
4. To improve medicines management and compliance with medications
5. To improve the quality of care for patients (and patient experience of their care)
6. To help people get the most out of life through effective self-management
   
About us:
The Sound Doctor was founded by Dominic Arkwright and Rosie Runciman and is a registered social enterprise.
Dominic worked as a reporter at the BBC for more than 20 years, mostly on Radio 4 's Today Programme as well as Newsnight and PM. He also presented discussion programme 'Off the Page' and 'The Call' on Radio 4.
Rosie Runciman also worked at the BBC for more than 20 years on Radio 4's Today programme, Newsnight, Radio 5 Live and at The World Service. She was Editor of Newshour and Assistant Editor at Five Live.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
  • For clinicians 
    • Complements and supports sessions
    • Sessions more focused and efficient to achieve better health outcomes
    • Reduces appointments, admissions and DNAs
  • For providers 
    • More efficient caseloads, better outcomes for patients, reduced waiting lists
    • Money saved through reduced numbers of GP appointments, hospital admissions and DNAs
Return On Investment (GPs)
Cost of TSD per patient per annum = £5.00
 
Average number of GP visits pre TSD = 3.7 appointments Average number of GP visits post TSD = 0.42 appointments
 
3 fewer appointments per TSD user x payment for each appointment of
£23.50 (NHS tariffs) = £70.50 per patient; an ROI of 1:14
 
Average number of GP DNAs pre TSD = 2.5 appointments Average number of GP DNAs post TSD = 0.5 appointments
 
2 fewer DNAs per TSD user x cost of each DNA of £36 (Kings Fund) = £72 per patient; an ROI of 1:14
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Benefits for patients
  
  • Empowers and encourages people’s engagement with their condition
  
  • Improves medicines adherence
  
  • Improves overall quality of care
  
  • Improves people’s experience of and satisafaction with their care
Current and planned activity: 
Who’s using The Sound Doctor
•  CCGs 
  • Barnsley, Gloucestershire, West Leicester, Wirral, Newcastle, Central London Community Health Trust
  
  • Hospital Trusts 
    • Guy’s and Tommy’s NHS Trust
    • Liverpool Heart and Chest Hospital
  
  • Other 
    • Philips Healthcare
    • All South London pharmacies
    • Jhoots Pharmacies
    • NAPC Practice Innovation Network
    •  
 
What is the intellectual property status of your innovation?:
We own the IP on all our content
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Dominic Arkwright 26/09/2016 - 16:02 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Sensely Ask NHS mobile app offering is a virtual nurse, Olivia, who guides the patient through clinical triaging or long term condition monitoring. Integrated and working with the NHS workforce. 
Overview of Innovation:
'Ask NHS' powered by Sensely provides patients and clinicians with improved access to NHS 111 and their local NHS services. Patients can talk through your symptoms in complete confidence with Nurse Olivia, a virtual nurse. If needed, Olivia she will arrange for a call back from a 111 Nurse to discuss symptoms further. Patients can also search NHS approved healthcare advice, schedule GP appointments and search opening times/locations of local healthcare services. It's the link for improving patient experience with Healthcare Providers and helping to cope with patient demand. Our key value proposition is to automate tasks for providers. We are Trusted , Empathetic, Personalised, Mobile First.

Sensely offers

- Mobile application platform that engages in natural conversations with patients.
- A clinician facing product which is data and process driven patient risk assessment.
- Direct Appointment Booking with GPs
- Service Locator (Integration with the NHS Directory of Services)
- Self Care Advice. Easily search through trusted NHS Choices healthcare advice and resources to gain a deeper understanding of conditions and treatments.
- Triage and Integration with Clinical Hubs (inc. NHS 111)
- Chronic Disease Management (CHF, COPD, Diabetes)

Olivia, our virtual nurse is connected with patients - 24/7 via their mobile device. She can help by answering their medical questions , measure their blood pressure, weight or glucose via blue tooth device, take a picture of their rash or swollen ankles and ask triage questions integrating with primary care services.

Olivia has been designed to embody the bedside manner of real healthcare professionals, and to be the clinician’s presence in patient’s life 24/7. Most importantly she does not only act as your virtual nurse - collecting vitals, scheduling appointments, offering health and wellness advice - she acts as your constant stream of accurate and clinically triaged information.

'Ask NHS' is powered by Sensely and delivered in collaboration with the NHS, NHS 111 and Odyssey by Advanced Healthcare. Visit http://www.sensely.com/asknhs to learn more.

For more information visit : http://www.asknhs.co.uk/ or email us at nhs@sensely.com
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Key Benefits

1) Saving the Clinician time. Pre Appointment Triage / Screening of patients, helping to prioritise those who need to be seen urgently - acting as admission avoidance tool. Sensely also offers the ability to directly book / cancel appointments into EMIS Web practices helping users to make an appointment when needed. Sensely supports CCGs achieve patient online programme initiatives through collaborative working we're providing the complete solution - one bundled app to navigate UK healthcare.

2) Improve health data. Using data captured through wearables. Sensely helps capture data and readings e.g blood pressure and weight measurements which can be subsequently filed to the GP patient record. Through the use of GPSoC APIs - data is recorded in a standard format using Readcodes ensuring high quality data capture and future analysis.

3) Using Sensely on smartphones provides clinicians with an ever-present clinical decision support tool that ensures they are providing patients with the best care plans.

4) Improved Patient Care - 24/7. Always available. Users can use the app to monitor their health and understand their body better. Subsequently, through Senselys integrated offering - the platform can alert a clinician when a patient who is being remotely monitored is flagged at being at risk. In the US - Sensely is used for supporting Chronic Care Management.

5) Improved efficiency to urgent care delivery. NHS 111 currently receives approx 30,000 calls per day. At an average of £13/call. This equates to £390,000 per day. Through the use of Sensely Artificial Nurse - we believe we can deal with a percentage of the self care queries / calls which are dealt with by a non clinical advisor (approx 20%) for which we could help save the NHS a potential of £78,000 per day.

6) Sensely interfaces with the Directory of Services which is utilised by NHS 111. Through the use of Service Locator - both clinicians and public can locate the right service at the right time. The tool ensures visibility of new services is transparent as possible to the right user. It is simple to use, accurate - always available tool where the content is locally administered by commissioning dos leads.
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
To solve the health industry operational problems, we created Sense.ly. Sense.ly is a mobile-first application platform that engages in natural conversations with patients to educate them, assess their medical conditions, answer their questions, and find the best possible sources of virtual assistance, telemedicine, or facility assistance. Our technology gives health providers and insurance companies the power to tailor unique customizable communication protocols and interaction workflows for each patient. The product offers the following capabilities:

1. Provides patients with a high quality “mobile virtual assistant” that proactively and reactively engages people in natural, personalized conversations and educational topics depending on their status, historical, and current issues.

2. Continuous monitoring of patients via mobile app

3. Connects patient/provider/payers with secure telemedicine and SMS platform

4. Delivers clinical, educational, and NHS/CCG information directly to the patient based on daily clinical picture, stage of treatment, claim progress, and immediate needs

5. Analyzes health data to calculate clinical improvement, compliance, readmission risk, and patient engagement.

6. Analyzes data-aggregates across disparate populations for the purposes of machine learning, disease prevention, risk/cost management, and clinical trials. Doctors and specialist use the information Sense.ly provides to optimize their team’s workflow around patients requiring immediate attention, while freeing up resources that would otherwise be allocated to less demanding cases.
Current and planned activity: 
Concept/Idea (No prototype, wireframes): Prescription Ordering

Working prototype developed (gathering feedback): Service Locator, Self Care, Direct Appointment Booking

Prototype with pilot users/clinical trials (test/validating): NHS 111 Odyssey Assessment integration with NHS 111, Medication Check

Prototype with paying customers: Patient Kiosk, Daily Check In

Fully developed product (paying customers, renewing contracts): Chronic Care Management
What is the intellectual property status of your innovation?:
The IP include 7 patent applications allowing us freedom to continuing to operate and innovate on our products and service lines by refining
our proprietary avatar conversation engine and clinical decision support system. The IP includes code, methods, and integrations defining the
conversation engine.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Anonymous 21/09/2016 - 14:58 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

IoT solutions for Integrated Health and Social Care Technology has been moved from Initial Submission to Publish 2 weeks 6 days ago
Biobanking Management Software - MbioLIMS has been moved from Initial Submission to Publish 1 month 2 weeks ago
Amplitude ​pro enterprise has been moved from Initial Submission to Publish 1 month 3 weeks ago
Sonia Hussein commented on Sensium: Early Detection of Patient Deterioration. Seamless ambulatory vital sign monitoring for the general ward population. 2 months 1 day ago
Sonia Hussein commented on Sensium: Early Detection of Patient Deterioration. Seamless ambulatory vital sign monitoring for the general ward population. 2 months 1 day ago

Active Campaigns